What’s been going on in the stem cell and regenerative medicine field over the past week and what are some worthwhile things to read? Today’s post has recommended recent reads from the scientific literature and the media. I’ve also got our weekly stem cell/regenerative medicine quiz question and the answer to last week’s. You can […]
Recommended reads: FDA warning, COVID updates, stem cell pubs Read More »
The FDA and its CBER branch have been doing a good job overall in the last 3+ years to tackle the unproven stem cell clinic problem, but lately on the stem cells for COVID-19 front there is reason for real concern. I believe the agency is taking on major risk overall by clearing a vast number of
Politics & FDA OK of 2 stem cell clinic COVID-19 efforts Read More »
Many are jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype. I’ve called this collective trend of
Overselling stem cells for COVID-19: WSJ article & UMN PR Read More »
This is a post by Mina Kim, a UC Davis student intern for The Niche blog, about the main types of cellular therapies being studied clinically for COVID-19. During the novel coronavirus pandemic with millions of COVID-19 cases, the development of safe and effective treatments for patients is vital. Cellular medicine treatments are one of
Review of 4 cell therapy types under study for COVID-19 Read More »
What’s new this week in terms of reads includes a stem cell/drug combo for diabetic wonderments healing, more documentation of patient harms from stem cell clinics, and a list of recommending papers. Adult stem cells/glaucoma drug combo promotes diabetic wound healing in mice From a team of my UC Davis School of Medicine colleagues led
Weekly stem cell reads: diabetic wound healing, clinic bad outcomes, pubs list Read More »
I’m doing an experiment today to see if people enjoy a mid-week splash of a few Wednesday recommended science reads and the first one collides with art. You can see Sunday’s recommended weekly reads here too. Also, be sure to visit our Facebook page if you have a moment and please like our page if
Mid-week rec reads: plague paleogenomics, bats, art, get new skin, & more Read More »
Here are our weekly recommended regenerative medicine and other notable science reads including a few things on COVID. It’s been quite an interesting week. “Junk DNA” is not so junky, role in differentiation NIH scientists showed how ancient retroviral genes, or “junk DNA”, may play a role in helping stem cells decide to become neurons. This
Weekly reads: ‘junk DNA’, COVID chaos, CRISPR CasΦ, & postdoc opps, more Read More »
The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe
New Mesoblast “COVID kid” stem cell study Read More »
Katie Thomas at the New York Times reports that BARDA has dropped considering funding applications for stem cells for COVID-19. The move is part of a larger shift in funding priorities away from lung treatments and toward vaccine development. The decision has puzzled and even angered some stem cell firms and researchers. BARDA stands for
BARDA drops funding of research into stem cells for COVID-19 Read More »
My weekly roundups of biomedical news tend to focus on stem cells, but I read more broadly so it’s not just stem cells but also CAR-T cells and a lot more this week. CAR-T cells as senolytics? A team led by Scott Lowe has a new intriguing paper in Nature on using CAR-T cells to
Weekly roundup: CAR-T cells, exosomes, trout cloning Read More »